ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On June 6, 2020, Kevin J. Ballinger, executive vice president and president, Interventional Cardiology, of Boston Scientific Corporation ("Boston Scientific" or the "Company"), informed the Company that he will resign effective July 3, 2020. Mr. Ballinger is resigning to take a chief executive officer position at a company that does not compete with Boston Scientific.

Joseph M. Fitzgerald, currently the Company's executive vice president and president, Rhythm Management, will change roles and serve as executive vice president and president, Interventional Cardiology, effective July 6, 2020.

Scott Olson, who currently serves as the Company's senior vice president, commercial general manager, Rhythm Management, has been appointed as senior vice president and president, Rhythm Management, effective July 6, 2020. Mr. Olson has also been appointed as an executive officer of the Company and will join Boston Scientific's Executive Committee, effective July 6, 2020.

(e) In connection with his appointment as executive vice president and president, Interventional Cardiology, Mr. Fitzgerald will receive on July 1, 2020 a grant of options to purchase shares of the Company's common stock having an aggregate value of $1.0 million on the date of grant. The options will vest in full on January 1, 2023. The grant will be made pursuant to the 2011 Boston Scientific Long-Term Incentive Plan (the "Plan") and will be subject to all provisions of the applicable award agreement under which it is granted and the Plan.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS





(d) Exhibits




Exhibit No.   Description
              Cover Page Interactive Data File (embedded within the Inline XBRL
104           document).

© Edgar Online, source Glimpses